Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents

被引：0
|
作者：
Hui Wang
Mao Li
Julie K. Rhie
David M. Hockenbery
Joseph M. Covey
Ruiwen Zhang
Donald L. Hill
机构：
[1] University of Alabama,Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Cancer Pharmacology Laboratory, Comprehensive Cancer Center
[2] National Cancer Institute,undefined
[3] Fred Hutchinson Cancer Research Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2005年 / 56卷
关键词：
2-Methoxyantimycin A; HPLC; Metabolism; Protein binding; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：291 / 298
页数：7
相关论文
共 50 条
  • [21] Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2
    King, J. N.
    Dawson, J.
    Esser, R. E.
    Fujimoto, R.
    Kimble, E. F.
    Maniara, W.
    Marshall, P. J.
    O'Byrne, L.
    Quadros, E.
    Toutain, P. L.
    Lees, P.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2009, 32 (01) : 1 - 17
  • [22] Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2
    Esser, R
    Berry, C
    Du, ZM
    Dawson, J
    Fox, A
    Fujimoto, RA
    Haston, W
    Kimble, EF
    Koehler, J
    Peppard, J
    Quadros, E
    Quintavalla, J
    Toscano, K
    Urban, L
    van Duzer, J
    Zhang, XL
    Zhou, SY
    Marshall, PJ
    BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (04) : 538 - 550
  • [23] PRECLINICAL PHARMACOLOGY STUDIES OF THE ANTITUMOR GLYCOSIDE PHYLLANTHOSIDE IN MOUSE AND BEAGLE DOG
    MOORE, DJ
    POWIS, G
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 354 - 354
  • [24] 11-Phenyl-[b,e]-dibenzazepine compounds: Novel antitumor agents
    Al-Qawasmeh, Raed A.
    Lee, Yoon
    Cao, Ming-Yu
    Gu, Xiaoping
    Viau, Stephane
    Lightfoot, Jeff
    Wright, Jim A.
    Young, Aiping H.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (01) : 104 - 107
  • [25] Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
    Yap, Timothy A.
    Walton, Mike I.
    Hunter, Lisa-Jane K.
    Valenti, Melanie
    Brandon, Alexis de Haven
    Eve, Paul D.
    Ruddle, Ruth
    Heaton, Simon P.
    Henley, Alan
    Pickard, Lisa
    Vijayaraghavan, Gowri
    Caldwell, John J.
    Thompson, Neil T.
    Aherne, Wynne
    Raynaud, Florence I.
    Eccles, Suzanne A.
    Workman, Paul
    Collins, Ian
    Garrett, Michelle D.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (02) : 360 - 371
  • [26] Preclinical pharmacology of neuroleptics: Focus on new generation compounds
    Richelson, E
    JOURNAL OF CLINICAL PSYCHIATRY, 1996, 57 : 4 - 11
  • [27] Novel Piperazinediones as Antitumor Agents
    Wang, Chun-Li
    Lee, On
    Hsiao, George
    Lian, Jang-Feng
    Cheng, Yu-Wen
    ANTICANCER RESEARCH, 2014, 34 (08) : 4013 - 4019
  • [28] Pharmacology Preclinical Pharmacokinetics of a Novel Nicorandil Prodrug
    Gupta, Pramod
    Khare, Atul
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 386 - 386
  • [29] Preclinical pharmacology of novel potent inhibitors of PARP
    Calabrese, CR
    Thomas, HD
    Srinivasan, S
    White, AW
    Boritzki, T
    Canon-Koch, S
    Zhang, K
    BRITISH JOURNAL OF CANCER, 1999, 80 : 93 - 93
  • [30] Design and preclinical evaluation of single agents with antitubulin and antiangiogenic activity as antitumor agents
    Gangjee, Aleem
    Pavana, Roheeth Kumar
    Zhang, Xin
    Ihnat, Michael
    Hamel, Ernest
    CANCER RESEARCH, 2012, 72
12345